Physician profile
Robin Vasan
NPI 1407343692
$2,640.72
in general payments reported to CMS, 2019-2025
29 companies · $2,197 in 2025
The $2,197 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $444 · 2025: $2,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,548 · Education: $77.97 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,547.75 |
| Education | $77.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $310.26 | 2024-2025 | Aquabeam System |
| Dendreon Pharmaceuticals LLC | $268.53 | 2024-2025 | Provenge |
| Coloplast Corp | $192.50 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $178.68 | 2024-2025 | |
| Endo USA, INC. | $157.11 | 2024-2025 | Xiaflex, Aveed |
| Baxter Healthcare | $145.26 | 2025 | Tisseel |
| Medtronic, INC. | $136.05 | 2024-2025 | Interstim |
| Tempus Ai, INC | $129.90 | 2025 | Xt Cdx |
| Astellas Pharma US INC | $111.57 | 2024-2025 | Xtandi |
| Sumitomo Pharma America, INC. | $101.89 | 2024-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $99.68 | 2024-2025 | Erleada |
| Boston Scientific Corporation | $93.28 | 2025 | Ams 700 |
| Urogen Pharma, INC. | $91.74 | 2025 | |
| Myriad Genetic Laboratories, INC. | $79.11 | 2024-2025 | Prolaris |
| Ferring Pharmaceuticals INC. | $79.06 | 2025 | Adstiladrin |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $71.53 | 2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $68.47 | 2025 | |
| Tolmar, INC. | $63.52 | 2025 | Eligard, Jatenzo |
| Abbvie INC. | $44.68 | 2024-2025 | |
| Calyxo, INC. | $38.34 | 2025 | Cvac Aspiration System |
| Blue Earth Diagnostics | $34.32 | 2025 | Posluma |
| Pfizer INC. | $25.11 | 2025 | |
| Sun Pharmaceutical Industries INC. | $21.48 | 2025 | |
| Teleflex LLC | $20.45 | 2025 | Urolift |
| Profound Medical Corp. | $17.26 | 2025 | Tulsa-Pro |
| Bioprotect Medical, INC. | $17.10 | 2024 | Bioprotect Balloon Implant System |
| Olympus America INC. | $16.80 | 2025 | Itind System |
| Becton, Dickinson and Company | $15.00 | 2025 | |
| Laborie Medical Technologies Corp. | $12.04 | 2025 | Aquarius Lt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Vasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.